Section 1: Introductory Statements and Governance

1ISG-030

ECONOMIC IMPACT OF BIOLOGICAL MEDICINES ON A THIRD LEVEL HOSPITAL

1ISG-029

CRANIOPLASTY: A REVIEW OF CUSTOMISED CRANIOPLASTY IMPLANTS

1ISG-028

BECOMING OF GRADUATE HOSPITAL PHARMACISTS: A FRENCH NATIONAL SURVEY

1ISG-027

CARBON FOOTPRINT OF A STERILISATION UNIT

1ISG-026

MULTIDISCIPLINARY DOCTOR-PHARMACIST COLLABORATION IN THE MANAGEMENT OF REFUNDS POLICIES OF OPHTHALMIC DRUGS AT SANT'ANDREA HOSPITAL , VERCELLI

1ISG-025

BUDGET IMPACT ANALYSIS OF BIOSIMILAR ADALIMUMAB VERSUS REFERENCE ADALIMUMAB

1ISG-024

BIOLOGICAL DRUGS IN THE TREATMENT OF IMMUNE MEDIATED INFLAMMATORY DISEASES: MONITORING OF PRESCRIPTION APPROPRIATENESS

1ISG-023

PHARMACOECONOMIC ANALYSIS OF REFERENCE BEVACIZUMAB: OPPORTUNITY FOR IMPROVED EFFICIENCY

1ISG-022

ECONOMIC ANALYSIS AFTER THE INCORPORATION OF BEVACIZUMAB BIOSIMILAR IN A THIRD LEVEL HOSPITAL

1ISG-021

INDIRECT COMPARISON OF BRIGATINIB VERSUS ALECTINIB IN THE ALK-POSITIVE NON-SMALL CELL LUNG CANCER

1ISG-020

COST SAVINGS IMPACT OF BIOSIMILARS: A LOCAL EXPERIENCE ON TRASTUZUMAB

1ISG-019

HOSPITAL PHARMACISTS AGED <45 YEARS: AN EMPLOYMENT STATUS AND JOB SATISFACTION SURVEY IN ITALY (submitted in 2019)

1ISG-018

APPLICATION OF A TIME SLOT MODEL IN ONCOLOGY: DELIVERY PLANNING AND PROCESS OPTIMISATION (submitted in 2019)

1ISG-017

IMPACT OF SUPPLY PROBLEMS IN A HOSPITAL PHARMACY SERVICE (submitted in 2019)

1ISG-016

ENVISIONING SUSTAINABILITY IN PERSONALISED MEDICINE: FONDO AIFA 5% AND THE ITALIAN EXAMPLE (submitted in 2019)

Pages